Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Antitumor agents described by Sagami

April 25, 1997

Genzyme Transgenics and NCI collaborate to expand cancer vaccine trials

April 24, 1997

Xytronyx's immunotherapy shows positive preclinical results

April 24, 1997

Triptorelin + melatonin for prostate cancer

April 23, 1997

Antiangiogenic effects of flavopiridol

April 23, 1997

EntreMed produces recombinant Angiostatin

April 22, 1997

ProScript licenses cell cycle regulation technology from Harvard Medical School

April 22, 1997

ImmunoGen's novel anticancer agent eradicates a human cancer in mice

April 22, 1997

Yamanouchi describes potent and selective steroid 17,20 lyase inhibitor

April 22, 1997

Princeton and Lilly disclose nonclassical antifolates

April 22, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...